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Abstract Testing for the presence of specific cell-surface
receptors (such as EGFR or HER2) on tumor cells is an
integral part of cancer care in terms of treatment decisions
and prognosis. Understanding the strengths and limitations of
these tests is important because inaccurate results may occur if
procedures designed to prevent false-negative or false-
positive outcomes are not employed. This review discusses
tests commonly used to identify and characterize cell-surface
receptors, such as the erythropoietin receptor (EpoR). First, a
summary is provided on the biology of the Epo/EpoR system,
describing how EpoR is expressed on erythrocytic progenitors
and precursors in the bone marrow where it mediates red
blood cell production in response to Epo. Second, studies
are described that investigated whether erythropoiesis-
stimulating agents could stimulate tumor progression in can-
cer patients and whether EpoR is expressed and functional on
tumor cells or on endothelial cells. The methods used in these
studies included immunohistochemistry, Northern blotting,
Western blotting, and binding assays. This review summarizes
the strengths and limitations of these methods. Critically an-
alyzing data from tests for cell-surface receptors such as EpoR
requires understanding the techniques utilized and
demonstrating that results are consistent with current knowl-
edge about receptor biology.
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Introduction
A current focus of oncology research is identifying tumor-
specific antigens, such as cell-surface protein receptors. Ther-
apeutic treatments have been developed to target some of
these receptors, and receptor expression is sometimes used
as a prognostic indicator. However, detecting the presence of a
cell-surface receptor on tumor cells does not guarantee that
inhibiting receptor activity will block tumor progression. For
example, colorectal tumors overexpressing epidermal growth
factor receptor (EGFR) respond to anti-EGFR antibody treat-
ment only in the absence of mutations that constitutively
activate KRAS [1]. In contrast, overexpression of human
epidermal growth factor receptor 2 (HER2) on breast-cancer
cells is highly predictive of response to anti-HER2 antibody
therapy [2]. Though cancer-treatment decisions and prognosis
often depend on knowing whether a protein receptor is pres-
ent, tests for detecting receptors can be unreliable. For exam-
ple, inaccurate outcomes from HER2-immunohistochemical
tests can occur due to issues with fixation, assay validation,
equipment calibration, testing reagents, and interpretation
criteria, leading to both false-positive and false-negative re-
sults [3, 4]. Because of the uncertainty of some HER2 labo-
ratory testing procedures, guidelines were published to im-
prove testing quality [5].
As new receptors are discovered and targeted therapies
developed, a basic understanding of the strengths and limita-
tions of methods for detecting, quantifying, and characterizing
cell-surface receptors becomes increasingly important for
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cancer treatment/prognosis and for interpreting data. Ampli-
fied receptors can be identified by detecting increased gene-
copy number (via Southern blotting and fluorescence in situ
hybridization [FISH]) or increased mRNA levels (via reverse
transcriptase-polymerase chain reaction [RT-PCR], Northern
blotting, or microarray) (Table 1). Increased receptor-protein
levels can be detected in tissue sections (via immunohisto-
chemistry [IHC]), in cell homogenates (via Western blotting),
or on the surface of intact cells (via binding assays with
labeled-receptor ligand or flow cytometry with specific anti-
bodies). Evaluating the presence of functional protein in-
volves examining if downstream signaling or enhanced
growth/cell survival occurs after cell exposure to the receptor's
ligand. Any single method requires adequate controls and
confirmation of results to exclude false-positive and/or false-
negative outcomes.
To illustrate the strengths and limitations of various
methods for detecting the presence, expression, and function
of cell-surface protein receptors, we use examples from the
literature regarding the cell-surface erythropoietin receptor
(EpoR). Normally, EpoR is expressed on erythrocytic progen-
itors and precursors in bone marrow where it mediates red
blood cell production in response to erythropoietin (Epo)
produced by the kidneys (Fig. 1) [6]. Some clinical studies
have suggested that patients with cancer treated with recom-
binant human Epo (rHuEpo) or other erythropoiesis-
stimulating agents (ESAs) have decreased loco-regional con-
trol of tumor growth and/or decreased survival [7]. Potentially
explaining these observations, it has been hypothesized that
ESAs could bind and activate EpoR on tumor cells to promote
their growth and/or survival [8, 9] or stimulate EpoR on
endothelial cells to promote tumor angiogenesis [10]. How-
ever, other reports indicate that EpoR is not required for
normal development of organs or endothelium [11], there is
no clinical progression of tumors in response to ESAs, that
tumor and endothelial cells do not express functional EpoR,
and that some methods of testing for EpoR have led to false-
positive results [6, 12–14].
This review summarizes techniques commonly used to
identify cell-surface receptors in the context of the large
quantity of published EpoR research. The most commonly
used technique in clinical care, IHC, will be discussed.
Since evaluating the strengths and limitations of other
EpoR-detection methods requires background about normal
EpoR and erythropoiesis, general information about EpoR
biology will be briefly reviewed. Detailed information will
then be presented on techniques used to examine specific
aspects of EpoR expression, function, and hypothesized
roles in tumor progression/angiogenesis. To identify arti-
cles for inclusion in this narrative review, several broad
searches of the biologic and medical literature were carried
out using the Ovid systems (Medline, EMBASE, and
BIOSIS Previews).
Immunohistochemical staining
IHC is a widely used antibody-based test for detecting recep-
tors, such as HER2, in tumors. IHC testing requires an anti-
body that specifically recognizes the receptor (Table 1). Tissue
collection, fixation, and sectioning influence the ability of an
antibody to bind a receptor [5]; thus, controls are essential to
exclude false-negative and false-positive results. Further, in-
terpretation of results requires training on understanding and
quantifying outcomes (e.g., 0–3+ values in HER2 IHC
reporting) [5].
Although published guidelines exist on validating and
employing antibodies for IHC, these guidelines are not always
followed [15]. With EpoR, many commercially available anti-
EpoR antibodies are nonspecific in that they bind to non-target
proteins and other cell-matrix structures [16–18]. Notably,
there are currently no anti-EpoR antibodies with the sensitiv-
ity and specificity to detect EpoR by IHC, yet there are dozens
of IHC studies describing EpoR expression based on results
with antibodies shown to be nonspecific [6]. For example, an
association was earlier noted between staining intensities in
head and neck tumor sections (stained with the “anti-EpoR”
polyclonal antibody [C-20)] from Santa Cruz Biotechnology
Inc.) and the clinical outcomes of the patients who were
treated with ESAs [8]. However, several groups of investiga-
tors subsequently demonstrated that C-20 produces false-
positive signals because it binds to non-EpoR proteins. Fur-
thermore, in other studies, staining by the antibody neither
correlated with EpoR expression [19] nor could it differentiate
between EpoR-positive and EpoR-negative cells in IHC
(Fig. 2) [16–18]. One of the cross-reactive proteins that C-20
binds is heat-shock protein 70 (HSP-70), which was
misidentified as EpoR in Western blotting experiments [16].
HSP-70 levels increase with stress-response [20]. Control
experiments, using negative-control antibodies of the same
isotype or antigen blocking, may eliminate some, but not all,
types of false-positive results [14, 15].
Cell lines or tissues expressing/not-expressing EpoR
should be used as positive and negative controls, respec-
tively. However, few EpoR-positive cell types are available
[21]. EpoR-positive cells also need to express physiologi-
cally relevant levels of EpoR protein to be informative.
Purified-erythroid precursor cells that express EpoR and
are Epo-responsive are difficult to obtain in large quanti-
ties. Tissues such as placenta [22] or cell lines such as
HeLa [23], MCF-7 [24], or K562 [25], which have been
used as EpoR-positive controls, are not Epo-responsive
and express EpoR levels greatly below (>100-fold lower)
those of known Epo-responsive cells (e.g., erythroid pro-
genitor or UT-7/Epo human-leukemic cells) [21], thereby
raising questions about the validity of studies using them.
When a specific and sensitive EpoR antibody is applied,
EpoR is low to undetectable on immunostaining in non-
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myeloid cells or tumor cells [14, 26] which is consistent
with the low levels of EpoR transcripts in those cell types
[6, 21].
In summary, IHC is widely used to identify clinically
relevant receptors (EGFR, HER2), but proper controls should
be employed with all IHC testing to detect both false-
positive and false-negative results. Use of IHC to iden-
tify EpoR has been hampered by lack of specific EpoR
antibodies and of control cell types that clearly express/
do not express EpoR.
Table 1 Common laboratory techniques for examining the cell biology of a protein receptor
Detection method Strengths Limitations
Genomic amplification
FISH Localizes defect to cell Semi-quantitative
Localizes defect to chromosome May not correlate with gene expression
Array CGH Quantitative May not correlate with gene expression or protein synthesis
Localizes defect to specific region of chromosome Population baseda
Southern blotting Easy to perform Semi-quantitative
Moderately sensitive Population based
May not correlate with gene expression or protein synthesis
mRNA analyses
Northern blotting Determines transcript size Insensitive
Determines potential spliced variants Time consuming
Population based
May not correlate with protein synthesis
RT-PCR Easy to perform Population based
Moderately sensitive May not detect different spliced forms
Semi-quantitative May not correlate with protein synthesis
Q-RT-PCR (Real Time) Moderately difficult to perform Population based (unless laser-dissected samples)
Very sensitive May not detect different spliced forms
Quantitative May not correlate with protein synthesis
Microarray Easy to perform Population based
Moderately sensitive May not detect different spliced forms
Quantitative May not correlate with protein synthesis
Broad gene profiling
Protein analyses
ELISA Easy to perform Need well-validated antibodies
Moderately sensitive Population based
Quantitative May not detect different spliced protein forms
May not correlate with function
Western blotting Easy to perform Need well-validated antibodies
Moderately sensitive Population based
Semi quantitative May not correlate with protein function
Protein sizes confirmed Unable to determine location of expression in a cell
IHC Moderately difficult to perform Need well-validated antibodies
Moderately sensitive May not correlate with protein function
Semi-quantitative May not detect different spliced protein forms
Determine location of protein expression in cell
Binding assays Moderately sensitive Need well-validated reagents
Easy to perform May not correlate with protein function
Quantitative May be able to detect different spliced forms
Individual cell analysis if flow-cytometry based
FISH fluorescence in situ hybridization, CGH comparative genomic hybridization, RT-PCR reverse transcriptase-polymerase chain reaction, Q
quantitative, ELISA enzyme-linked immunosorbent assay, IHC immunohistochemistry
a Population based refers to an analysis of multiple cells instead of a single cell
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Biology of Epo and EpoR
Physiological role of EpoR
The inherent problems with many detection methodologies are
highlighted by EpoR where confusion exists about its role in
tumors. The principal function of the Epo/EpoR system is regu-
lation of erythropoiesis. Epo stimulates erythropoiesis by binding
and activating EpoR on the surface of erythrocytic progenitors in
the bone marrow (Fig. 1a) [6]. Endogenous Epo is produced
primarily in the kidneys and is regulated by oxygen tension. In
blood plasma, Epo levels are approximately 10–20 mU/mL
(5 pM), but can increase 1,000-fold with extreme hypoxia [6].
Interestingly, neither Epo nor EpoR are required for commitment
to the erythroid lineage or for proliferation and differentiation of
burst-forming units-erythroid (BFU-Es) to colony-forming units-
erythroid (CFU-Es) [27, 28]. However, Epo and EpoR are
crucial in vivo for the survival, proliferation, and terminal differ-
entiation of the CFU-Es and their progeny.
Adult human Epo-responsive erythroblasts, which have the
highest levels of EpoR, still have relatively low receptor
protein levels compared to other receptor types (approximate-
ly 100–1,000 cell-surface EpoRmolecules per cell). However,
EpoR possess a very high affinity for Epo (dissociation con-
stant [Kd] ∼100 pM) [29]. The EpoR density declines as cells
differentiate into proerythroblasts. At the normoblast stage,
cells stop dividing, extrude nuclei and mitochondria, and
become reticulocytes that enter circulation. Reticulocytes
and mature red blood cells do not express EpoR and are
















































Fig. 1 The process of erythropoiesis. Erythroid progenitors in the bone
marrow that depend on Epo and EpoR for differentiation into mature red
blood cells (a). The signaling pathways stimulated by EpoR upon binding
to Epo (b). EpoR erythropoietin receptor, Epo erythropoietin, RBCs red
blood cells. Adapted from Biologics: Targets and Therapy, Volume 6,
Elliott S and Sinclair AM, The effect of erythropoietin on normal and
neoplastic cells, pages 163–89, Copyright (2012), with permission from
Dove Medical Press Ltd [6]
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EpoR transcription and translation
EpoR expression in erythropoietic tissues is not influenced by
Epo [28, 30]. Rather, EpoR-gene transcription is controlled by
erythroid-specific transcription factors, including GATA-1
[31] and stem-cell leukemia (SCL) protein [32], and EpoR
transcript levels correlate with GATA1 and SCL transcript
levels [6]. Thus, cell types lacking GATA-1 and SCL (e.g.,
those in non-hematopoietic tissues) express lower levels of
EpoR transcripts [13]. EpoR mRNA is translated into a 508
amino-acid protein, which is translocated to the plasma mem-
brane and transported to the cell surface [33, 34]. During this
process, a signal peptide is removed and a carbohydrate chain
added, resulting in a transmembrane protein with a calculated
molecular mass of 56 to 57 kDa [16]. To be Epo-responsive,
cells must express EpoR on the cell surface [16]. In cells that
express EpoR, however, <10 % of EpoR protein appears on
the cell surface; the remainder is degraded into intracellular
EpoR fragments that can be detected with specific EpoR
antibodies [12, 21, 35, 36].
EpoR activation and downstream signaling
EpoR protein does not possess intrinsic tyrosine-kinase activ-
ity and requires accessory factors (e.g., Janus kinase 2
[JAK2]) for cell-surface transport and downstream signaling
[37, 38]. EpoR is activated when a single Epo molecule binds
two cell-surface EpoRmolecules and effectively “cross-links”
them (Fig. 1b) [39–42]. Epo binding induces cross-
phosphorylation of EpoR and JAK2 [6, 43]. This activates
downstream proteins such as signal transducer and activator of
transcription 5 (STAT5), extracellular-signal regulated kinase
(ERK), and phosphatidylinositol-3 (PI3) kinase/AKT path-
ways [44]. Following activation, negative regulators of EpoR
down-modulate responses [45, 46].
Preclinical EpoR studies: from mRNA expression
to functional testing
mRNA expression: PCR, Northern blotting, and microarray
Presence of EpoR mRNA is necessary, but not sufficient, for
the expression and functionality of EpoR protein. EpoR
mRNA must be translated into protein that is translocated to
the cell surface. These processes involve multiple and limiting
molecular factors. Published techniques for detecting EpoR
mRNA in solid-tumor cells include RT-PCR (including real
time quantitative RT-PCR), microarray, and Northern blotting
[13, 47, 48]. As with IHC, positive and negative controls are
required. The mRNA levels must be evaluated, as sufficient
levels are needed for EpoR protein synthesis, surface expres-
sion, and function (recall that low levels of EpoR may not be
physiologically relevant and further that <10 % of EpoR
protein is expressed on the cell surface). RT-PCR is sensitive
and can detect low (basal) levels of mRNA transcripts, but at
the cost of potentially nonspecific amplification and with
questions about the significance of the detection. Northern
blotting is less sensitive, but since it uses electrophoreses to
separate mRNA samples by size, this parameter can be used to
eliminate some false positive data. Microarrays allow for a
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Fig. 2 Examples of false-positive IHC using commercial non-specific
EpoR antibodies. Wild-type and EpoR knockout-mouse embryos stained
with non-specific “anti-EpoR” M-20 antibody (a, c ) and rabbit-IgG
antibody (negative control) (b, d). IHC in cell lines positive (UT-7/Epo)
and negative (769-P, MCF-7) for EpoR using non-specific “anti-EpoR”
C-20 antibody (e, g, i) and rabbit-IgG antibody (negative control) (f, h, j).
Adapted with permission: Blood 2006;107:1892–1895 [16]
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analysis of multiple samples to provide definitive and quanti-
tative results.
The above specified techniques have enabled detection of
EpoR mRNA in some tumor and normal cells outside the
erythroid compartment, but at relatively low quantities (at 10-
1,000-fold lower levels than in positive controls) [6, 13, 19,
26, 47, 49]. Unlike known oncogenes such as HER2 and
EGFR , EpoR mRNA is not elevated when tumor samples
are compared with normal samples [47, 50, 51]. Reports
suggesting otherwise were based on non-quantitative or un-
controlled RT-PCR studies [49].
In summary, methods of detecting EpoR mRNA are sensi-
tive, but interpreting results requires controls to detect false-
positive data combined with quantitative methods to deter-
mine if mRNA levels are adequate to produce physiologically
relevant amounts of functional EpoR protein.
Western blotting
Receptor protein can be detected by tests such as IHC
(discussed earlier) and Western blotting. These tests require
an antibody that specifically binds the receptor of interest.
Western blotting involves separating proteins from a cell
homogenate according to size, immobilizing them on a mem-
brane, and using an antibody to detect a specific protein
(Fig. 3). Since cell homogenates are used, intracellular and
cell-surface proteins cannot be distinguished. Like IHC,
Western blotting can involve antibodies that cross-react with
non-target proteins, particularly if non-target proteins contain
a region with structural similarity to the target protein (Fig. 3).
This problem occurs frequently with polyclonal antibodies but
even monoclonal antibodies can show nonspecific cross reac-
tivity to non-target proteins, especially when sensitive detec-
tion methods are used. Given that EpoR is expressed at low
levels, cross-reactivity and false-positive results are partic-
ularly problematic with immunologic techniques. Confi-
dence is increased in a positive result if the “band” detected
corresponds to the correct size of the target protein. How-
ever, false-positive results can occur if a non-specific anti-
body recognizes a band of the correct size that is not the
target protein as has occurred when using commercial anti-
EpoR polyclonal antibodies such as M20 from Santa Cruz,
Inc. [14].
Western blot methodologies have been employed exten-
sively in attempts to detect EpoR in extracts from tumors and
tumor-cell lines. Positive results have been reported, but most
came from studies that used antibodies with insufficient
specificity/sensitivity to detect EpoR and that only rarely used
appropriate control-cell types to exclude false-positive results
[16, 49]. Thus, incorrect proteins have been misclassified as
EpoR [14, 16].
The full-length EpoR protein migrates at approximately
59 kDa with polyacrylamide gel electrophoresis (Fig. 4)





















Fig. 3 Specific and non-specific
antibody binding to proteins on a
Western blot. Cell homogenates
are separated by size and proteins
are detected with antibodies. A
specific antibody will bind one
particular protein (a). A non-
specific antibody will bind off-
target proteins (b). Antibody
binding can be detected with a
second antibody that emits a
signal (c, d)
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polyclonal C-20 EpoR antibody was reported to detect a
putative EpoR of 66 kDa (Fig. 4) [16, 18]. However, this
66-kDa protein was identified as the cross-reacting HSP-70
that has some sequence homology to EpoR. When using a
specific monoclonal anti-EpoR antibody suitable for Western
blotting (such as monoclonal anti-EpoR antibody A82), a 59-
kDa EpoR protein can be detected in erythroid cell extracts
but not in tumor biopsies [14] or most tumor-cell lines [21].
When EpoR protein was detected in cell lines, protein levels
were 10- to 1,000-fold lower than those in cells known to bind
or respond to Epo [13, 21].
Binding assays
The presence of cell-surface receptor protein on live cells can
be determined by binding assays with labeled ligand or by
flow cytometry with labeled antibodies to the receptor. How-
ever, non-specific binding is possible even with high-affinity
ligands [52]. In addition, structural changes to the ligands can
be introduced through the labeling process, which can in-
crease off-target binding. As with IHC and Western blotting,
the specificity and sensitivity of antibodies used for flow
cytometry needs to be demonstrated.
Binding assays using labeled forms of Epo or anti-EpoR
antibodies with flow cytometry have been used to detect cell-
surface EpoR protein. 125I-rHuEpo or biotinylated-rHuEpo
binding was detected on erythroid and some myeloid-cell types
with a dissociation constant (Kd) of ∼100 pM [29, 53, 54].
However, in controlled experiments, no binding of either 125I-
rHuEpo or of specific anti-EpoR antibodies to non-
hematopoietic cells or primary-tumor cells was detected [21,
47]. In a survey of 61 non-hematopoietic tumor-cell lines, only
one cell line had detectable (low level) EpoR protein on the cell
surface [21]. Other binding studies suggested that EpoR could
be detected on some non-hematopoietic tumor-cell lines [55].
In these studies, however, the Kd (10,000–16,000 pM) was
100-fold higher than that in EpoR positive-control cells, sug-
gesting nonspecific binding.
Functional receptor testing
An alternative to direct measurements of receptors is to ex-
amine responses to ligand addition, thereby demonstrating
that the receptor is not only present but functional. Such
methods can be very sensitive but can also be prone to false-
positive results. Determining if a cell-surface receptor is func-
tional requires demonstrating: (1) presence of intracellular-
signaling networks responsive to binding of receptor ligand;
(2) signaling occurs with relevant concentrations of receptor
ligand; and (3) receptor concentrations are high enough to
provide relevant signal strength. Similar to direct testing
methods, appropriate controls must be used to detect false-
positive and false-negative results.
1. Appropriate intracellular-signaling networks must be
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Fig. 4 Western blots showing non-specific and specific binding of EpoR
antibodies to cellular proteins. The 59-kDa EpoR protein is shown
(arrow) in positive controls FLAG-EpoR and UT-7/Epo. Nonspecific
C-20 antibody binds EpoR and other proteins (asterisk) (a). Specific-
antibody A82 binds EpoR and EpoR fragments but not other proteins (b).
Adapted with permission: Blood 2006;107:1892–1895 [16] and J.
Immunol Methods 2010;352:126–139 [12]
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Even if receptor mRNA or cell-surface proteins are detect-
ed, it is still necessary to demonstrate that intracellular-
signaling networks are activated in response to the ligand
binding the receptor. Demonstrating receptor activation can
involve detecting phosphorylation of intracellular signaling-
pathway proteins known to operate downstream of the acti-
vated receptor in normal, responsive cells. Since ERK and
AKT act downstream of EpoR in erythroid cells, activation of
EpoR can be assessed by using antibodies that recognize
phosphorylated epitopes of ERK and AKT. As noted above,
such experiments require demonstration of antibody specific-
ity and appropriate sensitivity. In some studies, ESA admin-
istration to tumor-cell lines increased phosphorylation of
ERK [56, 57]. However, ERK and AKT act downstream
of multiple ligand/receptor complexes [58] and can be
phosphorylated in response to changes in culture medium,
pH, temperature [59], and bacterial lipopolysaccharide [60,
61], offering the possibility of false-positive results. Further,
substances that can promote cell growth under certain
conditions are found in Epo formulations, such as in serum
or in bovine-serum albumin protein preparation used to
stabilize rHuEpo. These substances can also induce signal-
ing comparable to that observed in some ESA experiments
with cell lines [59].
Demonstrating phosphorylation of the downstream signal-
ing molecules JAK2 and STAT5 is more specific to EpoR
activation than demonstrating ERK and AKT phosphoryla-
tion. However, investigators have not always evaluated phos-
phorylation of JAK2 and STAT5. For example, Gewirtz et al.
[56] and Lester et al. [57] reported that rHuEpo stimulated
ERK phosphorylation in MCF-7 breast-cancer cells, but did
not evaluate effects on phosphorylation of STAT5 or JAK2. In
addition, other investigators have been unable to duplicate
those ERK results [18, 21], and control experiments suggest
that the positive effects were likely due to contaminants or to
medium changes, emphasizing the need for controls in such
studies to rule out false-positive effects. Additionally, since
EpoR requires accessory factors (e.g., JAK2) for transport to
the cell surface and for signaling [38], examination of the
phosphorylation status of JAK2 or STAT5 would be informa-
tive. However, such experiments are difficult to perform and
negative results have been reported. Therefore, other indirect
methods have been used. For example, inhibitors of JAK2
(e.g., AG490) were used to examine potential EpoR-mediated
effects with positive results reported. An assumption of such
experiments is that the inhibitors are specific to EpoR. Though
AG490 inhibits multiple kinases, it has little/no inhibitory
effect on JAK2 in vitro and, therefore, would not impact the
EpoR signaling pathway [62]. Thus, data using such JAK2
inhibitors must be interpreted with caution.
2. Receptor signaling must occur in response to relevant
ligand concentrations.
In several studies, there was increased proliferation of
tumor-cell lines on Epo addition, but with supraphysiological
Epo levels that were 10- to 1,000-fold greater than the max-
imum plasma level observed in patients receiving approved
Epo doses. For example, one report described how culturing
cells in a medium containing 250,000 mU/mL rHuEpo result-
ed in EpoR-mediated tyrosine phosphorylation [63]. With
administration of such high Epo doses, false-positive results
can occur due to non-specific vehicle effects or low-level
growth-promoting contaminants.
3. Enough receptor must be present to provide a meaningful
response.
Studies suggest that EpoR-protein levels are very low in
tumors and tumor-cell lines. As one example, MCF-7 breast-
cancer cells have a total of only 100 EpoR dimers/cell vs the
∼10,000 receptors (surface plus cytoplasmic EpoR) seen in
erythroid progenitors [21] but have been reported to respond
to Epo addition. Given the inefficient transport of EpoR to the
cell surface, the number of EpoR molecules available for
ligand binding on MCF-7 cells would be very low. Accord-
ingly, there is conflicting data with MCF-7 cells as Laugsch
et al. [18] and other groups [21] were unable to confirm
reports that rHuEpo stimulated proliferation of MCF-7 and
other cell lines where EpoR levels are very low. Another
confounding factor is that non-hematopoietic cells and tumor
cells may not have the same signaling networks found in
erythroid-progenitor cells or may have constitutive activation
of pathways. Either can render the cells nonresponsive to
growth factor challenge. Thus, cells may not respond to
Epo, even with high-level EpoR expression. Consistent with
this, forced overexpression of EpoR in some factor-dependent
myeloid cells or solid-tumor cell lines does not result in Epo
responsiveness [64, 65].
Apart from cell culture work, another approach is to
employ animal experiments. Studies using rodent-tumor
models have indicated that ESA administration alone does
not stimulate tumor proliferation [49]. In addition, ESAs
could hypothetically inhibit the effects of concurrently ad-
ministered anticancer therapy. One report indicated that
rHuEpo alone had no effect on MCF-7 cell growth in
animals, but that tumor size increased in trastuzumab-
treated animals [66]. However, as noted above, MCF-7
cells express minimal levels of EpoR and in studies by
other groups, treating MCF-7 cells with Epo failed to
interfere with the antiproliferative and/or cytotoxic effects
of either bevacizumab or paclitaxel [67, 68].
In summary, demonstrating functional EpoR requires
proof that cell-surface EpoR molecules exist in adequate
concentration and that downstream signaling occurs in
response to relevant ligand concentrations. In addition,
tests must be performed using positive and negative
controls.
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EpoR mutations/amplification and Epo overexpression
Mutations in genomic-coding sequences of receptor genes can
be tumorigenic or alter the potential for receptors to signal.
These include mutations that constitutively activate a receptor,
increase gene-copy number (and ultimately gene-expression
level of a receptor), or alter factors that regulate protein
processing, which can lead to receptor overproduction. These
mutations are usually identified through specific DNA se-
quencing of the gene on genomic clones, through sequencing
of mRNAs encoding the protein (using PCR/cloning), or
through complete genome/transcriptome sequencing using
next-generation sequencing methodologies.
EpoR mutations
A mutation in murine EpoR , R129C, was identified that
results in EpoR dimerization and constitutive activation. In
mice, this mutation causes erythroid and granulocyte/
monocyte colony-expansion but not expansion of other he-
matopoietic lineages, indicating that nonmyeloid-cell types
have a limited response to activated EpoR [69–71].
To date, no EpoR mutations have been reported in any solid
tumors. EpoR-activating mutations have not been observed in
erythroleukemias [72, 73], and erythroleukemias are not asso-
ciated with alterations to chromosome 19 where the EpoR gene
is located [72]. EpoR-hyperactivity truncation mutations cause
erythrocytosis in humans [74, 75], but not leukemias or tumors
[72, 76]. When Gonda et al. [72] screened ten human cases of
erythroleukemia, no EpoR-gene mutations were found.
In summary, though EpoR hyperactivity can cause
erythrocytosis and erythroleukemia in mice, no evidence to
date suggests that EpoR hyperactivating mutations in humans
increase cancer risk or enhance tumor growth.
EpoR gene amplification
Amplification of certain oncogenic receptors (e.g., HER2 or
EGFR) is characteristic of some aggressive tumors. Amplifi-
cation of the EpoR gene has been detected in some cell lines
derived from AML, CML, and erythroleukemia patients (e.g.,
UT-7 and TF-1) consistent with their myeloid origin [77, 78].
This amplification may provide these cells with a growth
advantage when treated with ESAs. However, EpoR -gene
amplification is not a characteristic of solid tumors. A gene-
amplification analysis of 1,083 solid tumors showed that
EpoR-gene amplification was rare; overall, the EpoR-gene
frequency was similar to other non-oncogenes [47].
Epo overexpression
Another suggested theory is that long–term exposure to ele-
vated levels of Epomight induce tumors. However, this theory
is not supported by patients with mutations resulting in life-
time elevated-Epo levels. Increased cancer incidence is not
observed in patients with Chuvash polycythemia who have
increased levels of endogenous Epo [79, 80]. Similarly, people
living at high altitude (>3,000 ft) with chronically elevated
endogenous Epo have no increase in tumor incidence, tumor
mortality, or tumor recurrence compared with those living at
sea level [81]. In summary, elevated levels of endogenous Epo
do not appear to increase the incidence of cancer.
Angiogenesis
As an alternative to direct stimulation of tumors via resident
receptors, tumor growth may be increased if an activated
receptor stimulates angiogenesis. During angiogenesis, new
vessels arise from existing vessels through endothelial
branching, sprouting, migration, and proliferation [82, 83].
One hypothesis is that Epo or exogenous ESAs could stimu-
late tumor growth by activating EpoR on endothelial cells to
facilitate angiogenesis near tumors.
While several groups have reported detection of EpoR on
endothelial cells, those results are controversial because of the
same antibody non-specificity issues reported above for IHC
and Western blotting. When a specific EpoR antibody was
used to evaluate EpoR on endothelial cells [13], little EpoR
protein was detected. Further, rHuEpo does not appear to bind
to endothelial cells, and ESAs exerted no effect on endothelial
cells in controlled experiments performed in vitro or in vivo
[13, 84–86]. Studies in EpoR-null mutant mice expressing
EpoR exclusively in the hematopoietic lineage have shown
that the Epo–EpoR signaling pathway is not necessary for
endothelial cell development [11]. In tumor-xenograft studies,
no effect on angiogenesis was observed with ESAs [87–89].
In contrast to these data, there are positive results suggesting
ESAs can stimulate angiogenesis. For example, Yamaji et al.
[90] reported increased proliferation (as measured by thymi-
dine incorporation) of brain-capillary endothelial cells follow-
ing Epo addition but only when accompanied by a change in
medium. Though one group noted that angiogenesis increases
in chicken eggs treated with rHuEpo [91–93], there is no
cross-species activity of human Epo in chickens [94]. These
questionable studies highlight the importance of appropriate
controls to aid in interpretation of the data.
Conclusion
The presence of a specific cell-surface receptor can be detect-
ed using multiple methodologies with recommended standard
procedures involving (1) receptor-specific antibodies, (2)
binding of radiolabeled ligands (however, to be interpretable,
the experiments must include both negative and positive
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controls and quantification of results to confirm that receptor
levels correlate with known levels needed for function), and
(3) confirmation of receptor size at the appropriate molecular
mass (kilodaltons). Strategies and guidelines for these stan-
dard procedures have been published and should be followed
[12, 15, 26].
Given the complexity of the issues involved, growth-factor
receptor research in cancers should be evaluated in light of the
techniques and controls used. Limitations in these techniques
can lead to contradictory results as shown here regarding
research on whether functional EpoR is present on non-
erythroid cells.
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